Zelira shares rocket 28% before being placed on ice. Here's the latest.

Zelira shareholders will have to wait until Thursday to find out the company's latest results from the German regulator.

| More on:
a medical person in white coat, gloves and protective eyewear uses tools and a test tube to put cannabis buds into the tube for research purposes.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Zelira shares surged 28.57% to $1.98 each on Tuesday before entering a trading halt
  • The company is preparing to release the results from Germany's regulatory body, BfArM
  • It is expected Zelira shares will resume trading on or before this Thursday

The Zelira Therapeutics Ltd (ASX: ZLD) share price was put on ice in mid-afternoon trading on Tuesday after it rocketed 28.57%.

It followed the company's request that its shares be placed in an immediate trading halt.

Shares in the medicinal cannabis company were frozen at $1.98 apiece.

Why is the Zelira share price halted?

In a statement to the ASX, Zelira advised it is preparing to make an important announcement to investors.

This is in relation to the receipt of results from Germany's health regulator, BfArM.

Zelira requested the trading halt remain in place until Thursday 14 July or when the announcement is made, whichever comes first.

A brief rundown on Zelira

Founded in 2003, Zelira is a biopharmaceutical company focused on researching, developing, and commercialising clinically-validated cannabinoid medicines.

The company has a pipeline of cannabinoid-based medicines undergoing clinical development that are waiting for access to the German market.

This includes two products that Zelira launched in 2020, both of which are available in Australia.

The first is its HOPE product which aims to improve the health of people with autism spectrum disorder.

And the other product is Zenivol which helps people with chronic sleep disorder (insomnia).

Zelira share price snapshot

Despite today's euphoric gains, Zelira shares have lost almost 80% since this time last year.

When looking at year-to-date, the company's shares are down around 65%.

Notably, Zelira shares hit a multi-year low of 90 cents apiece last month before storming higher.

Based on valuation grounds, the company presides a market capitalisation of roughly $18.9 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »